Notably, immune checkpoint analysis showed that GPN1 expression was correlated with PD-1/PDL-1 and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), suggesting it may serve as a biomarker for predicting immune subtypes and response to immunotherapy in HCC. Here, GPN1 is linked to hepatocellular carcinoma.